We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Human Milk Fortification in Extremely Preterm Infants (N-forte)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03797157
Recruitment Status : Active, not recruiting
First Posted : January 9, 2019
Last Update Posted : December 13, 2022
Sponsor:
Collaborators:
Sahlgrenska University Hospital, Sweden
Region Uppsala
Vasterbottens lans landsting
Prolacta Bioscience
Region Stockholm
Information provided by (Responsible Party):
Thomas Abrahamsson, MD, PhD, Ostergotland County Council, Sweden

Tracking Information
First Submitted Date  ICMJE December 17, 2018
First Posted Date  ICMJE January 9, 2019
Last Update Posted Date December 13, 2022
Actual Study Start Date  ICMJE February 1, 2019
Actual Primary Completion Date September 1, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 12, 2020)
The incidence of the composite of necrotizing enterocolitis, culture-proven sepsis and mortality [ Time Frame: From birth until discharge from hospital (but not longer than gestational week 44+0) ]
An infant should have had any of these diagnoses to fulfil the criterion
Original Primary Outcome Measures  ICMJE
 (submitted: January 4, 2019)
The incidence of the composite of necrotizing enterocolitis, culture-proven sepsis and mortality [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
An infant should have had any of these diagnoses to fulfil the criterion
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 15, 2021)
  • The incidence of the composite of necrotizing enterocolitis and culture-proven sepsis [ Time Frame: From birth until discharge from hospital (but not longer than gestational week 44+0) ]
    An infant should have had any of these diagnoses to fulfil the criterion
  • The incidence of the composite of necrotizing enterocolitis culture-proven sepsis, bronchopulmonary dysplasia, retinopathy of prematurity and mortality (Mortality and morbidity index) [ Time Frame: From birth until discharge from hospital (but not longer than gestational week 44+0) ]
    An infant should have had any of these diagnoses to fulfil the criterion
  • Time to reach full enteral feeds [ Time Frame: From birth until discharge from hospital (but not longer than gestational week 44+0) ]
    The day of life the infant has received at least 150 mL/kg enteral feeds
  • Number of feeding interruptions [ Time Frame: From birth until discharge from hospital (but not longer than gestational week 44+0) ]
    Number of days feedings held for ≥12 hours or feeds reduced by >50% (ml/kg/d) not due to a clinical procedure or transitioning to the breast
  • Numbers of days with parenteral nutrition [ Time Frame: From birth until discharge from hospital (but not longer than gestational week 44+0) ]
    Number of days of parental amino acid and/or lipid infusion. Only days when the enteral feed <150mL/kg/day should be included
  • Number of large gastric aspirates per day [ Time Frame: From birth until discharge from hospital (but not longer than gestational week 44+0) ]
    ≥100% pre-feed volume (2 hours feeding volume if continuous feeding). Lower limit=2 ml/kg.
  • Stool frequency [ Time Frame: From birth until discharge from hospital (but not longer than gestational week 44+0) ]
  • Time to regain birth weight [ Time Frame: From birth until discharge from hospital (but not longer than gestational week 44+0) ]
  • Change in head circumference in centimeters [ Time Frame: At 7, 14, 21 and 28 days, the end of intervention (gestational week 34+0), gestational week 36+0, at discharge from neonatal ward (or at gestational week 44+0, whatever comes first) and at 2 years of age (corrected) and 5.5 years of age (uncorrected). ]
  • Change in weight in gram [ Time Frame: At 7, 14, 21 and 28 days, the end of intervention (gestational week 34+0), gestational week 36+0, at discharge from neonatal ward (or at gestational week 44+0, whatever comes first) and at 2 years of age (corrected) and 5.5 years of age (uncorrected). ]
  • Change in length in centimeters [ Time Frame: At 7, 14, 21 and 28 days, the end of intervention (gestational week 34+0), gestational week 36+0, at discharge from neonatal ward (or at gestational week 44+0, whatever comes first) and at 2 years of age (corrected) and 5.5 years of age (uncorrected). ]
  • The mortality incidence [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  • The incidence of necrotising enterocolitis: Bell´s stage II-III [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  • The incidence spontaneous intestinal perforation [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  • The incidence of abdominal surgery [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  • The incidence culture-proven sepsis [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  • The incidence of suspected sepsis, not culture-proven [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  • The incidence of pneumonia [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Pathological X-ray confirmed by an independent radiologist, need of increased respiratory support/oxygen and laboratory inflammatory response
  • The incidence of bronchopulmonary dysplasia [ Time Frame: At gestational week 36+0 ]
    Need of extra oxygen, continuous positive air pressure (CPAP) or ventilator at gestational week 36+0
  • The incidence of retinopathy of the prematurity [ Time Frame: From birth until gestational week 42+0 ]
    Classified into stage I-V. The diagnosis is set after gestational week 42+0
  • The incidence of intraventricular haemorrhage [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Classified into grade I-IV according to Papile
  • The incidence of periventricular leukomalacia [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Criteria according to de Vries
  • Number of days with intensive care [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Need of respirator or CPAP until discharge (not later than gestational week 44+0).
  • Length of stay at the hospital [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Gestational week and day at discharge (not later than gestational week 44+0).
  • Length of need of feeding tube [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Gestational week and day when the infant does not need it anymore (not later than gestational week 44+0)
  • Neurocognitive development at 2 years [ Time Frame: At 2 years of age ]
    Bayleys III, PARCA-R (Parental Report of Children´s Abilities-Revised) and ASQ-3 (Ages and stages questionnaire)
  • Prevalence of cerebral palsy at 2 years [ Time Frame: At 2 years of age ]
  • Prevalence of epilepsy at 2 years [ Time Frame: At 2 years of age ]
  • Prevalence of squint and/or impaired vision at 2 years [ Time Frame: At 2 years of age ]
  • Prevalence of impaired hearing at 2 years [ Time Frame: At 2 years of age ]
  • The number of infants needing extra oxygen and/or ventilatory support after discharge from the hospital at the neonatal period [ Time Frame: From gestational week 44 until 2 years of age ]
  • The incidence of wheeze and/or asthma [ Time Frame: From birth until 2 years of life ]
  • The incidence of severe infections after discharge from the neonatal unit [ Time Frame: From gestational week 44 until 2 years of age ]
  • The number of infants needing feeding tube after discharge from the hospital at the neonatal period [ Time Frame: From gestational week 44 until 2 years of age ]
  • The number of infants needing extra nutritional support after discharge from the hospital at the neonatal period [ Time Frame: From gestational week 44 until 2 years of age ]
  • The prevalence of neurocognitive development at 5.5 years [ Time Frame: At 5.5 years of age ]
    Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV TM) and Movement ABC-2: the total scale points as well as the points of sub scales (motor, cognitive, language) will be presented. The prevalence of infants with a realist below 2 standard deviations will be defined to have mental retardation.
  • The prevalence of cerebral palsy at 5.5 years [ Time Frame: At 5.5 years of age ]
  • The prevalence of epilepsy at 5.5 years of age [ Time Frame: At 5.5 years of age ]
  • The prevalence of squint and/or impaired vision at 5.5 years of age [ Time Frame: At 5.5 years of age ]
  • The prevalence of children with impaired hearing at 5.5 years of age [ Time Frame: At 5.5 years of age ]
  • The prevalence of wheeze and/or asthma at 5.5 years of age [ Time Frame: At 5.5 years of age ]
  • Microbiome composition in stool samples [ Time Frame: At 1, 2, 3 and 4 weeks of age and gestational week 36+0 ]
    The relative abundance and diversity of microbial taxa will be analyses with next generation sequencing and be related till the study intervention
  • Levels of subclasses of T and B cells and granulocytes in blood samples [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    T helper subsets (TH1, Th2, TH17, Treg), T cells subsets associated with the intestinal mucosa (gamma/delta-T cells, MAIT cells) and neutrophils will be assessed using masscytometry
  • Levels of immune markers in plasma [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    Pre planned analyses are anti-inflammatory (e.g. IL-10) and proinflammatory (e.g. TNF) cytokines and chemokines (e.g. CXCL11, CCL18).
  • Levels of growth factors in plasma samples [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    The levels of growth factors such as IGF-1 and the associated IGFBP-3 will be analysed.
  • Levels of lipids in plasma samples [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    Fatty acids in plasma
  • Levels of neurotransmitters in plasma samples [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    Neurotransmitters such as GABA and serotonin in plasma
  • Levels of metabolic peptides in urine samples [ Time Frame: At 1, 2, 3 and 4 weeks of age and gestational week 36+0 ]
    Metabolic peptide will be measured with proton nuclear magnetic resonance spectroscopy (NMR), liquid chromatography (LC) and mass spectroscopy couple to gas chromatography (GC-MC).
  • Levels of markers of central nervous system (CNS) damage in plasma samples [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    Markers of CNS damage such as neurofilament light protein will be measured in plasma
  • Levels of proteins in breast milk samples [ Time Frame: At 1, 2, 3 and 4 weeks of age and gestational week 36+0 ]
    Protein composition will be measured with multiplex methods
  • Levels of human milk oligosaccharides in breast milk samples [ Time Frame: At 1, 2, 3 and 4 weeks of age and gestational week 36+0 ]
    The levels of human milk oligosaccharides will be measured with high-performance anion-exchange chromatography with pulsed amperometric detection.
  • Health care costs [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    The number of days at each level of care will be recorded until discharge from the hospital (not longer than gestational week 44+0). The cost will be calculated by multiplying the number of days at each level of care by the average cost
Original Secondary Outcome Measures  ICMJE
 (submitted: January 4, 2019)
  • Time to reach full enteral feeds [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    The day of life the infant has received at least 150 mL/kg enteral feeds
  • Number of feeding interruptions [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Number of days feedings held for ≥12 hours or feeds reduced by >50% (ml/kg/d) not due to a clinical procedure or transitioning to the breast
  • Numbers of days with parenteral nutrition [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Number of days of parental amino acid and/or lipid infusion. Only days when the enteral feed <150mL/kg/day should be included
  • Number of large gastric aspirates per day [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    ≥100% pre-feed volume (2 hours feeding volume if continuous feeding). Lower limit=2 ml/kg.
  • Stool frequency [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  • Time to regain birth weight [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  • Change in head circumference in centimeters [ Time Frame: At 7, 14, 21 and 28 days, the end of intervention (gestational week 34+0), gestational week 36+0, at discharge from neonatal ward (or at gestational week 44+0, whatever comes first) and at 2 years of age (corrected) and 5.5 years of age (uncorrected). ]
  • Change in weight in gram [ Time Frame: At 7, 14, 21 and 28 days, the end of intervention (gestational week 34+0), gestational week 36+0, at discharge from neonatal ward (or at gestational week 44+0, whatever comes first) and at 2 years of age (corrected) and 5.5 years of age (uncorrected). ]
  • Change in length in centimeters [ Time Frame: At 7, 14, 21 and 28 days, the end of intervention (gestational week 34+0), gestational week 36+0, at discharge from neonatal ward (or at gestational week 44+0, whatever comes first) and at 2 years of age (corrected) and 5.5 years of age (uncorrected). ]
  • The mortality incidence [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  • The incidence of necrotising enterocolitis: Bell´s stage II-III [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  • The incidence spontaneous intestinal perforation [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  • The incidence of abdominal surgery [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  • The incidence culture-proven sepsis [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  • The incidence of suspected sepsis, not culture-proven [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  • The incidence of pneumonia [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Pathological X-ray confirmed by an independent radiologist, need of increased respiratory support/oxygen and laboratory inflammatory response
  • The incidence of bronchopulmonary dysplasia [ Time Frame: At gestational week 36+0 ]
    Need of extra oxygen, continuous positive air pressure (CPAP) or ventilator at gestational week 36+0
  • The incidence of retinopathy of the prematurity [ Time Frame: From birth until gestational week 42+0 ]
    Classified into stage I-V. The diagnosis is set after gestational week 42+0
  • The incidence of intraventricular haemorrhage [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Classified into grade I-IV according to Papile
  • The incidence of periventricular leukomalacia [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Criteria according to de Vries
  • Number of days with intensive care [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Need of respirator or CPAP until discharge (not later than gestational week 44+0).
  • Length of stay at the hospital [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Gestational week and day at discharge (not later than gestational week 44+0).
  • Length of need of feeding tube [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Gestational week and day when the infant does not need it anymore (not later than gestational week 44+0)
  • Neurocognitive development at 2 years [ Time Frame: At 2 years of age ]
    Bayleys III
  • Prevalence of cerebral palsy at 2 years [ Time Frame: At 2 years of age ]
  • Prevalence of epilepsy at 2 years [ Time Frame: At 2 years of age ]
  • Prevalence of squint and/or impaired vision at 2 years [ Time Frame: At 2 years of age ]
  • Prevalence of impaired hearing at 2 years [ Time Frame: At 2 years of age ]
  • The number of infants needing extra oxygen and/or ventilatory support after discharge from the hospital at the neonatal period [ Time Frame: From gestational week 44 until 2 years of age ]
  • The incidence of wheeze and/or asthma [ Time Frame: From birth until 2 years of life ]
  • The incidence of severe infections after discharge from the neonatal unit [ Time Frame: From gestational week 44 until 2 years of age ]
  • The number of infants needing feeding tube after discharge from the hospital at the neonatal period [ Time Frame: From gestational week 44 until 2 years of age ]
  • The number of infants needing extra nutritional support after discharge from the hospital at the neonatal period [ Time Frame: From gestational week 44 until 2 years of age ]
  • The prevalence of neurocognitive development at 5.5 years [ Time Frame: At 5.5 years of age ]
    Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV TM) and Movement ABC-2: the total scale points as well as the points of sub scales (motor, cognitive, language) will be presented. The prevalence of infants with a realist below 2 standard deviations will be defined to have mental retardation.
  • The prevalence of cerebral palsy at 5.5 years [ Time Frame: At 5.5 years of age ]
  • The prevalence of epilepsy at 5.5 years of age [ Time Frame: At 5.5 years of age ]
  • The prevalence of squint and/or impaired vision at 5.5 years of age [ Time Frame: At 5.5 years of age ]
  • The prevalence of children with impaired hearing at 5.5 years of age [ Time Frame: At 5.5 years of age ]
  • The prevalence of wheeze and/or asthma at 5.5 years of age [ Time Frame: At 5.5 years of age ]
  • Microbiome composition in stool samples [ Time Frame: At 1, 2, 3 and 4 weeks of age and gestational week 36+0 ]
    The relative abundance and diversity of microbial taxa will be analyses with next generation sequencing and be related till the study intervention
  • Levels of subclasses of T and B cells and granulocytes in blood samples [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    T helper subsets (TH1, Th2, TH17, Treg), T cells subsets associated with the intestinal mucosa (gamma/delta-T cells, MAIT cells) and neutrophils will be assessed using masscytometry
  • Levels of immune markers in plasma [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    Pre planned analyses are anti-inflammatory (e.g. IL-10) and proinflammatory (e.g. TNF) cytokines and chemokines (e.g. CXCL11, CCL18).
  • Levels of growth factors in plasma samples [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    The levels of growth factors such as IGF-1 and the associated IGFBP-3 will be analysed.
  • Levels of lipids in plasma samples [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    Fatty acids in plasma
  • Levels of neurotransmitters in plasma samples [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    Neurotransmitters such as GABA and serotonin in plasma
  • Levels of markers of central nervous system (CNS) damage in plasma samples [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    Markers of CNS damage such as neurofilament light protein will be measured in plasma
  • Levels of metabolic peptides in urine samples [ Time Frame: At 1, 2, 3 and 4 weeks of age and gestational week 36+0 ]
    Metabolic peptide will be measured with proton nuclear magnetic resonance spectroscopy (NMR), liquid chromatography (LC) and mass spectroscopy couple to gas chromatography (GC-MC).
  • Levels of proteins in breast milk samples [ Time Frame: At 1, 2, 3 and 4 weeks of age and gestational week 36+0 ]
    Protein composition will be measured with multiplex methods
  • Levels of human milk oligosaccharides in breast milk samples [ Time Frame: At 1, 2, 3 and 4 weeks of age and gestational week 36+0 ]
    The levels of human milk oligosaccharides will be measured with high-performance anion-exchange chromatography with pulsed amperometric detection.
  • Health care costs [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    The number of days at each level of care will be recorded until discharge from the hospital (not longer than gestational week 44+0). The cost will be calculated by multiplying the number of days at each level of care by the average cost
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Human Milk Fortification in Extremely Preterm Infants
Official Title  ICMJE Nordic Study on Human Milk Fortification in Extremely Preterm Infants: a Randomized Controlled Trial
Brief Summary

This is a randomised controlled multi-centre trial comparing the effect of diet supplementation of a human breast milk-based nutrient fortifier (H2MF®) with standard bovine protein-based nutrient fortifier in 222 extremely preterm infants (born before gestational week 28+0) exclusively fed with human breast milk (own mother´s milk and/or donor milk). The infants will be randomised to receive either the human breast-milk based H2MF® or the standard bovine protein-based nutrient fortifier when oral feeds have reached <100 ml/kg/day.

The randomised intervention, stratified by centre, will continue until the target gestational week 34+0. The infant must not be fed with formula during the intervention period. The allocation will be concealed before inclusion, but after randomisation the study is not blinded.

Primary endpoint of the intervention is the composite variable necrotizing enterocolitis (NEC), sepsis and mortality.

The enrolled infants are characterised with clinical data including growth, feeding intolerance, use of enteral and parenteral nutrition, treatment, antibiotics and complications collected daily in a study specific case report form from birth until discharge from the hospital (not longer than gestational week 44+0). A follow up focusing on neurological development, growth and feeding problems will be performed at 2 years of age (corrected) and 5.5 years of age.

Detailed Description

This is a randomised controlled multi-centre trial comparing the effect of diet supplementation of a human breast milk-based nutrient fortifier (H2MF®) with standard bovine protein-based nutrient fortifier in 222 extremely preterm infants (born before gestational week 28+0) exclusively fed with human breast milk (own mother´s milk and/or donor milk). The infants will be randomised to receive either the human breast-milk based H2MF® or the standard bovine protein-based nutrient fortifier when oral feeds have reached <100 ml/kg/day. If fortification with extra enteral lipids is needed during the intervention period, the infants receiving H2MF® will be supplemented with the human milk-based Prolact CR®, while the infants receiving standard bovine protein-based fortification will be supplemented with the standard lipid products used at the unit. The study subject will be enrolled at level III neonatal intensive care unit (NICU)s. Only infants with a home clinic with the logistics to maintain the intervention until gestational week 34+0 will be included.

The randomised intervention, stratified by centre, will continue until the target gestational week 34+0. The infant must not be fed with formula during the intervention period. The allocation will be concealed before inclusion, but after randomisation the study is not blinded. It would not be possible to prescribe the fortifier and prepare of the breast milk in a blinded fashion, since the fortifiers are not exactly equal in nutrient content and also look different. Instead the assessment of several of the outcomes will be made blinded, such as the assessment of X-ray images in NEC cases.

The enrolled infants are characterised with clinical data including growth, feeding intolerance, use of enteral and parenteral nutrition, treatment, antibiotics and complications collected daily in a study specific case report form from birth until discharge from the hospital (not longer than gestational week 44+0). A follow up focusing on neurological development, growth and feeding problems will be performed at 2 years of age (corrected).

Since it is often difficult to distinguish between the diagnoses of NEC and sepsis, and their clinical consequences, the investigator's primary endpoint of the intervention is the composite variable NEC, sepsis and mortality. Secondary endpoints are feeding intolerance and other severe complication such as Bronchopulmonary dysplasia (BPD), Retinopathy of prematurity (ROP) and neurological impairment. Stool, urine and blood samples are also collected for microbiology, metabolomic and immunology analysis in order to study underlying mechanisms. Health economic analyses will be made to evaluate the costs and benefits of an introduction of human milk-based fortifier in NICUs in the Nordic countries.

Analyses will be conducted using an intention to treat approach. An evaluation will be performed when 20 infants have been included to evaluate feasibility and make it possible to adjust the protocol for the remaining part of the study. Safety analyses will be performed by an independent data and safety monitoring board (DSMB) when 50, 100 and 150 infants have been included. A sample size re-estimation will be made by an independent statistician when 150 infants have been included. Thus, the definitive sample size might be increased (never decreased) based on this interim analysis. The study can be terminated before 322 infants have been enrolled based on a decision of the sponsor and the DSMB, if the primary outcome is significantly lower (with a significance level <0.001) in the H2MF® than in the standard fortification group in the interim analysis made after 150 infants have completed the neonatal period. The study subject will be enrolled at level III NICUs in the Nordic Countries. All study subjects will be followed during the neonatal period until discharge (not longer than gestational week 44+0) and also be included in a follow up at 2 and 5.5 years of age based on the national follow up program for extremely preterm infants.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE
  • Necrotizing Enterocolitis
  • Sepsis
  • Mortality
Intervention  ICMJE
  • Dietary Supplement: H2MF
    H2MF is a human milk-based breastmilk fortifier for preterm infants
  • Dietary Supplement: Bovine milk-based fortifier
    Bovine milk-based fortifier is the standard breast milk fortifier in Sweden
Study Arms  ICMJE
  • Experimental: H2MF
    Human milk-based breast milk fortifier
    Intervention: Dietary Supplement: H2MF
  • Active Comparator: Standard fortifier
    Standard care: bovine milk-based breast milk fortifier
    Intervention: Dietary Supplement: Bovine milk-based fortifier
Publications * Jensen GB, Ahlsson F, Domellof M, Elfvin A, Naver L, Abrahamsson T. Nordic study on human milk fortification in extremely preterm infants: a randomised controlled trial-the N-forte trial. BMJ Open. 2021 Nov 23;11(11):e053400. doi: 10.1136/bmjopen-2021-053400.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: December 12, 2022)
229
Original Estimated Enrollment  ICMJE
 (submitted: January 4, 2019)
222
Estimated Study Completion Date  ICMJE December 31, 2027
Actual Primary Completion Date September 1, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Gestational age at birth 22+0-27+6: based on prenatal ultrasonography.
  • Enteral feeds < 100 mL/kg/day at the day of randomisation.
  • Written informed consent from the legal guardians of the infant.
  • The home clinic of the infant has the logistics of maintaining the intervention until gestational week 34+0

Exclusion Criteria:

  • Lethal or complicated malformation known at the time of inclusion
  • Chromosomal anomalies known at the time of inclusion
  • No realistic hope for survival at the time of inclusion
  • Gastrointestinal malformation known at the time of inclusion
  • Abdominal surgery before the time of inclusion
  • Participation in another intervention trial aiming at having an effect on growth, nutrition, feeding intolerance or severe complications such as NEC and sepsis
  • Infants having nutrient fortifier or formula prior to randomisation
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE Child, Adult, Older Adult
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Sweden
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03797157
Other Study ID Numbers  ICMJE RegionOstergotland
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Thomas Abrahamsson, MD, PhD, Ostergotland County Council, Sweden
Original Responsible Party Thomas Abrahamsson, Ostergotland County Council, Sweden, Principal Investigator, Md PhD
Current Study Sponsor  ICMJE Thomas Abrahamsson, MD, PhD
Original Study Sponsor  ICMJE Thomas Abrahamsson
Collaborators  ICMJE
  • Sahlgrenska University Hospital, Sweden
  • Region Uppsala
  • Vasterbottens lans landsting
  • Prolacta Bioscience
  • Region Stockholm
Investigators  ICMJE
Principal Investigator: Thomas R Abrahamsson, MD, PhD Region Ostergotland
PRS Account Ostergotland County Council, Sweden
Verification Date December 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP